Overview
This document serves as a formal correction to the 2019 study published in Nature Communications regarding the molecular mechanisms of tobacco-induced immune evasion in lung cancer. The correction addresses technical inaccuracies in visual data and provides missing experimental metadata essential for reproducibility.
Addressing Technical Inaccuracies
The primary technical correction involves Figure 1f, which utilized immunofluorescence to visualize PD-L1 expression and nuclear localization (via DAPI staining) in human bronchial epithelial cells (16HBE) and lung cancer cells (H460) treated with Benzo[a]pyrene (BaP). The original publication contained an incorrect DAPI image for the BaP-treated 16HBE cells.
Enhancing Experimental Transparency
Beyond the visual correction, the authors have provided critical metadata that was omitted in the initial report:
- Sample Sizes ($n$): Clarification of the number of biological replicates and independent experiments. Most cell-based assays were performed in triplicate, while in vivo mouse models utilized groups of $n=3$ to $n=10$.
- Statistical Methods: The correction confirms the use of Student’s $t$-tests for determining significance, with error bars representing standard deviation (sd). Significance thresholds are now explicitly defined as $*P < 0.05$ and $**P < 0.01$.
- Supplementary Data: A legend for Supplementary Figure 1 was added, detailing the use of quantitative real-time PCR (qRT-PCR) to measure PD-L1 mRNA levels across three independent experiments.
Conclusion
While the fundamental scientific conclusions regarding the role of the Aryl hydrocarbon receptor (AhR) in mediating PD-L1 expression remain unchanged, these corrections are vital for the integrity of the scientific record. Readers are advised to consult this correction alongside the original 2019 article, as the original PDF and HTML versions have not been updated to reflect these changes.
Summary updated